The miR-106b-25 microRNA (miRNA) cluster is a candidate oncogene in human prostate cancer. Here, we report that miRNAs encoded by miR-106b-25 are upregulated in both primary tumors and distant metastasis. Moreover, increased tumor miR-106b expression was associated with disease recurrence and the combination of high miR-106b and low CASP7 (caspase-7) expressions in primary tumors was an independent predictor of early disease recurrence (adjusted hazard ratio ¼ 4.1; 95% confidence interval: 1.6-12.3). To identify yet unknown oncogenic functions of miR-106b, we overexpressed it in LNCaP human prostate cancer cells to examine miR-106b-induced global expression changes among protein-coding genes. The approach revealed that CASP7 is a direct target of miR-106b, which was confirmed by western blot analysis and a 3 0 -untranslated region reporter assay. Moreover, selected phenotypes induced by miR-106b knockdown in DU145 human prostate cancer cells did not develop when both miR-106b and CASP7 expression were inhibited. Further analyses showed that CASP7 is downregulated in primary prostate tumors and metastatic lesions across multiple data sets and is by itself associated with disease recurrence and disease-specific survival. Using bioinformatics, we also observed that miR-106b-25 may specifically influence focal adhesion-related pathways. This observation was experimentally examined using miR-106b-25-transduced 22Rv1 human prostate cancer cells. After infection with a miR-106b-25 lentiviral expression construct, 22Rv1 cells showed increased adhesion to basement membrane-and bone matrix-related filaments and enhanced soft agar growth. In summary, miR-106b-25 was found to be associated with prostate cancer progression and disease outcome and may do so by altering apoptosis-and focal adhesion-related pathways.
INTRODUCTION
MicroRNAs (miRs) are non-coding RNAs that influence mRNA stability and translation by binding to regulatory sites located primarily in the 3 0 -untranslated region (UTR) of the targeted transcripts. 1 Recently, miRs have been found to exert tumor suppressor activity, while others act as oncogenes. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Previously, we and others observed that miR-106b, miR-93 and miR-25, which are encoded by the polycistronic miR-106b-25 cluster, are upregulated in primary human prostate tumors. 11, [13] [14] [15] This miR cluster is located at 7q23.1 within the MCM7 gene locus that is amplified in many human epithelial cancers. 16 Moreover, 7q23.1 locus amplifications are among the most frequently acquired genetic alterations in human prostate tumors and are associated with early disease recurrence, 17 suggesting a key role of locusencoded miR-106b-25 in disease outcome.
Sequence homology indicates that miR-106b-25 has functions similar to those of the miR-17-92 cluster, a known oncogene. 3 Despite this similarity, only miR-106b-25, but not miR-17-92, is dysregulated in prostate cancer. 11, 13 MiR-106b-25 targets the transcription factor and pRB-binding partner, E2F1, and its expression was shown to impair the transforming growth factorb signaling pathway. 18 We and others reported that miR-106b inhibits p21/WAF1, while miR-25 targets the apoptosis regulator, Bim, leading to chemoresistance of cancer cells. 13, [18] [19] [20] [21] Recently, it was discovered that miR-106b-25 cooperates with its host gene, MCM7, in cell transformation by targeting the tumor suppressor, PTEN.
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To further define the oncogenic role of the miR-106b-25 cluster in prostate cancer progression and outcome, we analyzed a large data set consisting of primary tumors, disease metastases and disease-recurrence status. 22 We also over-expressed miR-106b and the complete miR-106b-25 cluster in cultured human prostate cancer cells. These experiments revealed that miR106b-25 is associated with prostate cancer progression and recurrence and has a potential role in the regulation of focal adhesion-related pathways. In addition, caspase-7 (CASP7) was identified as a novel target of miR-106-25 and a marker of disease outcome. 1 Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA; RESULTS Increased expression of miR-106b-25 in metastatic prostate cancer and prostate cancer-prone TRAMP mice In the current study, we examined the expression of miR-106b-25 in a large publicly available data set consisting of miR and mRNA expression profiles for 28 non-cancerous tissues, 99 primary tumors and 14 distant metastases with patient data for disease recurrence. 22 Consistent with our previous findings, 13 all clusterencoded miRs were significantly upregulated (on average 1.5-fold) in the primary tumor tissues (Figure 1a) . Moreover, expression of these miRs tended to further increase in the metastatic lesions (on average 1.3-fold; significant for miR-93 and miR-25, upregulated albeit not statistically significant for miR-106b) when compared with the primary tumors ( Figure 1a) . A similar pattern was observed for miR-32 and miR-375 comparing tumor with noncancerous tissue, but these miRs were not found to be further upregulated in the metastatic lesions, whereas the candidate tumor suppressor, miR-101, 9 was downregulated in both tumors and in metastasis (Supplementary Figure S1) . MiR-32 is encoded by the C9orf5 locus and is a functional homolog of miR-25, and is, like miR-375, a candidate prostate cancer oncogene. 13 We also explored whether miR-106b-25 is upregulated in the prostate of cancer-prone TRAMP mice. 23 Using quantitative real-time PCR assays for mature miRs, we found that cancer-prone TRAMP mice at 20 week of age have a 2-4-fold increased miR-106b-25 cluster expression in their prostate when compared with the same-age wild-type control animals (Figure 1b ), corroborating our hypothesis that this miR cluster is a prostate cancer oncogene.
Elevated levels of miR-106b and miR-32 are associated with prostate cancer recurrence Because expression of the miR-106b-25 cluster is increased in both primary and metastatic prostate cancer, we next investigated whether increased expression of miR-106b-25 family members is associated with disease-free survival. Within the Taylor data set, 98 of the 99 primary tumors with miR and mRNA expression data had follow-up data for biochemical recurrence status. KaplanMeier survival analysis showed that patients with an abovemedian expression of miR-106b were at a significantly increased risk of early recurrence (Figure 2a ). Cox proportional hazards regression estimated a recurrence hazard ratio of 2.7 (95% confidence interval, 1.1-7.3; comparing above-versus belowmedian expression of miR-106b). This association was weaker for miR-93 (P ¼ 0.063), a miR-106b homolog, while no association with recurrence was observed for miR-25 (Figures 2b, c) . By contrast, above-median expression of the miR-25 homolog, miR-32, was found to be associated with early recurrence (Supplementary Figure S1) . Additional comparisons showed that miR-375, but not miR-101, was as well associated with disease recurrence, with miR-375 behaving like an oncogene (Supplementary Figure S1) . To assess the relative contribution of miR-106b target genes to early disease recurrence, we plotted the enrichment of predicted miR-106b target genes among all recurrence-associated transcripts in the Taylor data set on a hazard ratio scale for disease recurrence (Figure 2d ). This analysis showed that mRNAs, whose decreased expression is associated with early recurrence, are significantly enriched for miR-106b target genes, consistent with the hypothesis that miR-106b exerts its function by targeting tumor suppressor-encoding mRNAs.
CASP7 is a candidate miR-106b target associated with disease recurrence To identify key mRNA targets of miR-106b involved in processes underlying disease recurrence in human prostate cancer, we interfaced transcripts related to recurrence in the data set by Taylor et al. 22 with mRNAs that were experimentally altered in LNCaP cells after transfection with pre-miR-106b oligos. LNCaP cells were transfected with these mimics of mature miR-106b or with scrambled oligo controls, and mRNA expression alterations were examined after 24 h. Introduction of pre-miR-106b into LNCaP cells not only affected gene expression but also increased cell density in a 6-day assay (Supplementary Figure S2) , indicating a proto-oncogenic function of miR-106b under these conditions. Our experiment yielded a short list of transcripts that were at least 1.5-fold downregulated by miR-106b at the Po0.01 significance level (Supplementary Table S1 ). Additional analyses confirmed that this list of genes was significantly enriched for TargetScan 5.0-predicted miR-106b targets (P ¼ 6 Â 10 À 17 , Fisher's exact test) and for cell death-related genes (Po0.01), based on a Gene Ontology Biological Processes mapping analysis. The list of death-related genes included CASP7 and Fas-activated kinase, among others. When we examined the union between the downregulated transcripts in the miR-106b-transfected LNCaP cells (cutoff: Po0.01 and 1.5-fold expression change), recurrence-associated transcripts in the Taylor data set (Po0.05 for continuous variable in the Cox proportional hazards regression) and all TargetScan 5.0-predicted miR-106b targets, only four transcripts, CASP7, CROT, COQ2 and NFIB, were found to be in common (Figure 3a) . Kaplan-Meier analysis with a dichotomized expression of these mRNAs showed that above-median expression of CASP7, COQ2 and CROT was associated with a delayed disease recurrence in prostate cancer patients (Figures 3b-d) , consistent with the hypothesis that miR-106b target genes are tumor suppressors in prostate cancer. The association of CASP7 with prostate cancer outcome was validated in a second data set, 24 as shown by its significant association with prostate cancer-specific (overall) survival in Supplementary Figure S3 . By contrast, expression of the miR-106b-25 host gene, MCM7, was not found to be associated with survival in our analyses. When we combined miR-106b and CASP7 expression to predict recurrence, those tumors that had above-median miR-106b expression and below-median CASP7 expression were significantly more likely (Po0.001) to fall into the early recurrence group than the other tumors (Supplementary Figure S4) , with a markedly increased recurrence hazard for CASP7 low/miR-106b high tumors in the Cox regression analysis, even after adjustment for age, Gleason score and clinical stage (adjusted hazard ratio ¼ 4.1; 95% CI: 1.6-12.3). Because we had previously observed that miR-106-25 inhibits therapy-induced apoptosis in human prostate cancer cells, 13 we focused on CASP7 for further analyses in which the Figure 2 . Association of miR-106b-25 cluster expression with recurrence-free survival. Kaplan-Meier curves for recurrence-free survival of prostate cancer patients based on the expression of (a) miR-106b, (b) miR-93 and (c) miR-25 in 98 primary tumors from the Taylor et al. 22 data set. Tumor miR expression was dichotomized into high (n ¼ 49) and low (n ¼ 49) based on median miR expression in the gene arrays. Log-rank test P-values are shown. (d) Enrichment of miR-106b target genes among recurrence-associated transcripts ('% miR-106b Targets') on a hazard ratio (HR) scale for disease recurrence. HRs were calculated for all mRNAs using their expression in the Taylor data set as a continuous variable in the Cox proportional hazards regression analysis. Graph shows the percentage of these mRNAs predicted to have a miR-106b target site as the HR scale increases or decreases (HRo1 is indicative of a tumor suppressor with HR calculated for high vs low mRNA expression). The analysis revealed that mRNAs whose decreased expression is associated with early recurrence ('tumor suppressor') are enriched for miR-106b target genes. Targetscan 5.0 was used to identify mRNAs with a predicted miR-106b-binding site. There was a statistical significant difference (Po0.0001) in the relative abundance of predicted miR-106b target genes between mRNAs associated with delayed recurrence (HRo1, high vs low mRNA expression) and mRNAs associated with an early recurrence (HR41, high vs low mRNA expression), with a higher number of miR106b target genes being associated with delayed recurrence when highly expressed in prostate tumors ('tumor suppressors'). mRNA expression of CASP7 was evaluated in additional prostate cancer data sets. This approach showed that CASP7 expression is downregulated in primary human prostate tumors, in distant metastases and in tumors with a high Gleason score across multiple data sets (Supplementary Table S2 ).
miR-106b directly targets CASP7
We next focused our research on CASP7 being a novel direct target of miR-106b. Three putative miR-binding sites in the 3 0 -UTR of the CASP7 mRNA transcript were identified, including a miR-106 7mer-8m seed-site sharing homology with miR-17/20a/20b/93/ 519d. Sequence alignment of this putative site showed evolutionary conservation within mammalian species (Figure 4a ). To further validate our initial observation that miR-106b downregulates CASP7 mRNA, three prostate cell lines, RWPE-1, 22Rv1 and LNCaP cells, were transfected with pre-miR-106b and CASP7 protein expression was evaluated. These cell lines were previously found to express endogenous miR-106b, with RWPE-1 cells having the lowest expression and both 22Rv1 and LNCaP cells having an elevated expression. 13 MiR-106b downregulated CASP7 protein levels in all cell lines (Figure 4b ), whereas no effect was observed for CASP3 or with the unrelated miR-1, indicating that the observed effect of miR-106b on CASP7 protein levels was specific. Likewise, knockdown of miR-106b led to increased expression of its targets CASP7 and PTEN in DU145 cells (Figure 4c) . A direct effect of miRs on the expression of a target gene is best demonstrated with a reporter assay for miR-seed-site interactions. Thus, we tested whether the expression of CASP7 is directly influenced by miR-106b and generated psiCHECK reporter constructs containing a renilla luciferase gene fused to the complete 3 0 -UTR of CASP7 containing either wild-type or mutant miR-106b seed-site sequences (shown in Figure 4a ). Luciferase assays performed after co-transfecting wild-type or mutant reporter constructs along with pre-miR-106b or control oligos into LNCaP cells showed that miR-106b significantly reduces luciferase levels with the wild-type CASP7 3 0 -UTR (about 66% inhibition), but not with the mutant CASP7 3 0 -UTR (Figure 4d ), indicating that miR106b exerts an inhibitory effect through this site. However, the mutant seed sequence did not completely abrogate the inhibitory effect of miR-106b (29% inhibition remained). As we could not identify another predicted target sequence for miR-106b in the 3 0 -UTR, target sequence-independent effects of miR-106b on CASP7 expression may exist. Lastly, we examined whether regulation of CASP7 expression by miR-106b is a component of miR-106b function. We applied lock nucleic acid (LNA)-mediated knockdown of miR-106b and CASP7 in DU145 cells. Transfection of DU145 cells with LNA-106b antagomirs downregulated miR-106b by 80-90% with concurrent upregulation of CASP7 (see Figure 4c ), whereas transfection with LNA-CASP7 antagomirs either alone or in combination with LNA106b efficiently downregulated CASP7 expression (Figure 5a ). Applying this methodology, we observed that LNA-106b nucleofection increased staurosporine-induced apoptosis in DU145 cells ( Figure 5b ), as one may expect from a loss of anti-apoptotic miR-106b. This increase in apoptosis was not observed when LNA106b was co-nucleofected with LNA-CASP7 (LNA-106b/CASP7), indicating that targeting CASP7 is likely important for at least some of the anti-apoptotic properties of miR-106b.
MiR-106b-25 cluster influences extracellular matrix (ECM) binding and enhances soft agar growth
To identify yet unrecognized functions of miR-106b-25, a bioinformatics-based analysis of the Taylor data set was performed that identified KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways with the highest enrichment for miR-106b-25 targets. Based on correlations between miR and mRNA expression in normal, primary tumor and metastatic prostate tissues, five major KEGG clusters were identified (Supplementary Figure S5) . mRNAs that correlated with miR-106b-25 expression in human prostate tissues were found to be most significantly enriched for transcripts encoding cell adhesion genes and ECM-associated receptors. To experimentally explore the relationship between miR-106b-25 expression and cell adhesion, we infected 22Rv1 prostate cancer cells with a lentiviral expression vector for miR-106b-25. Stably infected 22Rv1 cells, selected after a fluorescence-activated cell sort for GFP (green fluorescent protein)-positive cells, were found to have a 1.5-2-fold increased expression of the mature miRs, which mimics the fold upregulation of these miRs in primary human prostate tumors and metastatic lesions. When the adhesion of the 22Rv1 cells to fibronectin, laminin, vitronectin, and to collagen types 1 and 4 was examined, miR-106b-25-overexpressing 22Rv1 cells were found to have an increased adhesion to laminin and the two collagens when compared with vector control-infected cells (Figure 6a ). Perhaps most interesting was the fact that miR-106b-25 induced enhanced binding to collagen type 4, a bone-associated filament. 22Rv1 cells, transduced with the miR-106b-25 expression vector, also showed an increased capacity to grow in soft agar (Figure 6b ). When we conducted the same soft agar growth assay with DU145 cells overexpressing the miR-106b-25 cluster, we observed a more modest increase in soft agar growth by these inheritably more malignant cells (Supplementary Figure S6) , which was nevertheless consistent with the 22Rv1 cell-based observations. Because of the potential limitation using overexpression of miR106b-25 in DU145 cells, we also knocked down miR-106b and CASP7 in these cells to examine how miR-106b loss affects ECM binding and soft agar growth, and whether the resulting phenotype is CASP7-dependent. As shown in Figures 6c and d , knockdown of miR-106b led to reduced ECM binding and reduced soft agar growth, which was reversible by additional knockdown of CASP7. These data are consistent with the results from the 22Rv1 cell experiment, pointing to an oncogenic role of miR-106-25 in ECM binding and soft agar growth.
DISCUSSION
In this study, we report that the apoptosis executioner, CASP7, is a novel candidate target of miR-106b-25 and show that inhibition of CASP7 is likely important for at least some of the anti-apoptotic and oncogenic properties of miR-106b. The finding is consistent with our previous finding that miR-106b-25 expression attenuates drug-induced apoptosis in prostate cancer cells. 13 We also show that miR-106b-25 can alter cell-adhesion properties of prostate cancer cells, which is in agreement with the observation that integrins are candidate targets of miRs encoded by this cluster. 25 Moreover, miR-106b-25 and its target, CASP7, were found to be associated with prostate cancer development and disease recurrence, with miR-106b-25 behaving like an oncogene and CASP7 like a tumor suppressor. Notably, the combination of high miR-106b and low CASP7 expressions in primary tumors was a predictor of disease recurrence and should be further evaluated in future studies. Lastly, our study provided novel evidence that the miR-25 homolog, miR-32, is upregulated in human prostate cancer and is a candidate predictor of recurrence.
MiR-106b-25 encodes three miRs of which two, miR-106b and miR-93, are functional homologs having the same predicted mRNA targets. 26 MiR-106b-25 is located within the MCM7 locus at 7q23.1, and both MCM7 and miR-106b-25 are proposed oncogenes in human prostate cancer based on their functions. This classification is further supported by our current study and research by others that link 7q23.1 amplifications and a gene signature containing miR-106-25 to disease prognosis. 15, 17 The growing evidence that both MCM7 and miR-106b-25 are oncogenic may also explain why specifically the 7q23.1 locus containing miR-106b-25, but not the homologous miR-17-92 locus, is commonly amplified in human prostate tumors.
Using an exploratory approach, Martens-Uzunova et al.
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generated a prognostic predictor for postoperative outcome in prostate cancer based on deep-sequencing results for non-coding RNAs. Notably, their predictor contained all the family members of miR-106b-25. Of the three miR-106b-25-encoded miRs, miR-25 did not show an association with disease recurrence in our study although we found that the expression correlation between all cluster-encoded miRs was high in the tumors (miR-106b with miR-93, r ¼ 0.95; miR-106b and miR-93 with miR-25 is r ¼ 0.85). We suspect that a greater variance in miR-25 abundance across tumors may have weakened the association of miR-25 with disease recurrence. We also hypothesize that its homolog, miR-32, may have a dominant function in human prostate cancer biology, explaining why miR-32, but not miR-25, is a candidate predictor of recurrence. This argument is supported by the recently observed increased expression of miR-32, but not miR-25, in the castration-resistant disease. 27 An important function of miR-106b-25 in tumor biology is the inhibition of PTEN, which is a target of both miR-25 and miR106b. 11, 28 Others showed that the miR-106b-25 cluster targets the E2F1 pathway and the cell cycle inhibitor, p21/WAF1, while overexpression of just miR-106b can override therapy-induced growth arrest through p21/WAF1 inhibition. 13, [18] [19] [20] [21] 29 In this function, miR-106b-25 promotes cell-cycle progression and hyperproliferation, which is consistent with our observation that miR-106b-transfected prostate cancer cell lines tend to have increased proliferation rates.
The regulation of E2F1 expression by the miR-106-25 cluster may also protect prostate cancer cells from E2F1-induced apoptosis as this protein has a dual function in cell-cycle control and apoptosis. Bim (BCL2L11) is another pro-apoptotic gene that is targeted by the miR-106-25 cluster. 18 Upregulation of Bim was first observed in mice deficient of the miR-17-92 cluster and was later shown to be targeted by miR-25 and miR-32. 13, 18, 20, 29, 30 Our finding that CASP7 is a target of miR-106b-25 adds it to the list of pro-apoptotic genes that are inhibited by miR-106b-25. We also observed that miR-106b downregulates Fas-activated kinase, which is involved in Fas ligand-induced apoptosis. CASP7 is one of the two ubiquitously expressed executioner caspases consisting of CASP3 and CASP7, but there is no evidence that miR-106b-25 targets CASP3. CASP7 expression was associated with prostate cancer outcomes and was downregulated in human prostate tumors across multiple data sets, indicating a previously unrecognized tumor-suppressor role of this gene in human prostate cancer. To our best knowledge, a mutation in CASP7 has never been described for human prostate tumors, and other studies indicate that CASP7 does not appear to be a classical tumor suppressor that is inactivated by mutations in solid tumors. 31 Nevertheless, the results from the survival analysis suggest that upregulated CASP7 has a tumor-suppressor function in human prostate tumors. We hypothesize that the combined inhibition of pro-apoptotic E2F1, Bim, Fas-activated kinase, CASP7 and PTEN provides miR-106b-25-expressing cancer cells with a survival advantage in cancer progression. Downregulation of cell death-inducing integrins, like integrin-beta8, which is a target of miR-106b and miR-93, 25 may further support anchorageindependent growth.
Analysis of the intersection between miR and mRNA expression in human prostate tumors indicated that miR-106b-25 may alter cell-adhesion properties of prostate cancer cells. These data led us to study ECM binding of 22Rv1 cells in response to moderate miR-106b-25 overexpression. The experiment provided preliminary evidence that miR-106b-25 enhances binding to bone filaments like collagen type 4 in at least this prostate cancer cell line. This observation was further supported by a miR-106b-knockdown experiment in DU145 cells, showing that miR-106b loss in these cells led to decreased ECM binding. These findings are quite opposite with that of observations with MCF-7 (Michigan Cancer Foundation-7) breast cancer cells. 32 However, breast cancer bone metastases are primarily osteolytic (bone degrading), whereas prostate cancer bone metastases are osteoblastic (bone forming), which leads to increased collagen formation as part of their function. Thus, the metastatic profile of prostate and breast cancer cells can be very different in ECM assays. For further evaluation, we cultured highly metastatic PC-3 cells and the 22Rv1 cells under ECM assay conditions. Interestingly, only PC-3 cells showed increased proliferation in the presence of ECM proteins (Supplementary Figure S7) , suggesting that binding to ECM proteins and growth in this assay could be a metastatic feature in prostate cancer. Our finding potentially links miR-106b-25 expression to bone metastasis.
Although future experiments should lead to the identification of adhesion molecules that are influenced by miR-106b-25 in human prostate epithelial cells, a second mechanism involving miR-106b may have led to increased numbers of adherent cells in the ECM assays. Our data showed that the effect of miR-106b on cell adhesion is influenced by CASP7. We suspect inhibition of an anoikis-type apoptosis mechanism after CASP7 knockdown under the assay condition. Thus, miR-106b-25 upregulation may lead to increased ECM binding by affecting adhesion and by increasing apoptosis resistance in the assay, which is likely an important survival phenotype in cancer metastasis. This hypothesis is further supported by the observation that miR-25 also inhibits Bim expression. 33 Bim has been shown to be a key mediator of anoikistype apoptosis. 34 In summary, we made the novel observation that miR-106-25 is associated with prostate cancer progression and disease prognosis and identified CASP7 as a novel target of this cluster, further corroborating previous observations that 7q23.1 locus amplifications are key events in human prostate cancer outcome. Future studies should explore whether miR-106-25 enhances bone invasion of human prostate cancer cells and examine the underlying mechanisms of this process and miR-106b-25-induced anchorage-independent survival.
MATERIALS AND METHODS

Cell lines and TRAMP mice
All cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). TRAMP mice 23 were obtained from the Jackson Laboratory (Bar Harbor, ME, USA).
RNA isolation and gene array analysis of mRNA expression in cell lines
Total RNA was isolated with TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). Genome-wide mRNA expression profiles were analyzed on the MicroRNA-106-25 cluster in prostate cancer RS Hudson et al GeneChip Human Genome U133A 2.0 array (Affymetrix, Santa Clara, CA, USA). To examine miR-106b-induced mRNA expression profiles, three experiments were performed for oligo control and pre-miR-106b treatments. Normalized and raw expression data from this study were deposited in GEO (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE34893.
Quantitative real-time PCR analysis of miR expression
For quantification of mature miRs, Human TaqMan MicroRNA Assays (Applied Biosystems, Carlsbad, CA, USA) and reagents from the TaqMan MicroRNA Reverse Transcription Kit were used, as previously reported. 35 Expression levels of miRs were normalized to U6 RNA levels and presented as 2 À DCt . miR oligonucleotide transfections Pre-miR mimic oligonucleotides (Ambion, TX, USA) were used at a 30-nM final concentration in the experiments. Briefly, cells were plated in six-well plates at 2.5 Â 10 5 cells per well, grown for 48-72 h and then switched to antibiotic-free media before transfection. Next, 1.5 ml oligos at 50 mM and 4 ml Lipofectamine 2000 (Invitrogen) were added individually to 250 ml of Opti-MEM (Invitrogen) and then combined and incubated for at least 20 min, before being added to the cells (2.5 ml media in total).
Knockdown experiments with LNA technology
To knockdown miR-106b (LNA-106b) or CASP7 (LNA-CASP7), DU145 cells were nucleofected with either scrambled Exiqon miRCURY Lock Nucleic Acid (control LNA), a miR-106b Power Inhibitor (Vedbaek, Denmark), or LNA modified Silencer Select siRNAs for CASP7 (LNA-CASP7) using Nucleofector Technology (Lonza, Inc., Walkersville, MD, USA) and the Cell Line Nucleofector Kit L (Lonza, Inc.) optimized for DU145 cells. Briefly, DU145 cells were suspended in 100 ml of nucleofection solution, mixed with 2 ml of a 50-mM of LNA oligonucleotides per 1 Â 10 6 cells and nucleofected using the nucleofector program A-023.
Infection of 22Rv1 cells with a lentiviral miR-106b-25 expression construct 22Rv1 prostate cancer cells were infected with a lentiviral vector that encodes the miR-106b-25 cluster, as described. 13, 18 Cells were cultured in 1:3 diluted viral stock for 48 h and then expanded in standard culture medium. Infection of cells with this vector or the control vector (Tween/ pRRL.CMV.PGK.GFP.WPRE) resulted in an almost 100% infection efficiency, as determined by the co-expressed GFP reporter gene.
3
0 -UTR reporter construct cloning and luciferase reporter assay
The 3 0 -UTR of CASP7 was PCR amplified from human genomic DNA using 200 nM of primers No. 7489 and No. 7490 (Operon Biotechnologies, Huntsville, AL, USA). Mutant CASP7 3 0 -UTR was designed to have a 4-bp change within the miR-106b seed site and was made by overlap extension PCR. The final PCR products contained the wild-type or mutant 3 0 -UTRs flanked by Gateway attB1 and attB2 sites. PCR products were recombined into pDonr253 using the Gateway BP recombination reaction (Invitrogen). Sequences were verified throughout the entire cloned region. These entry clones were subcloned into a Gateway-modified version of the psiCHECK2 expression vector containing luciferase and renilla genes, with renilla utilized as the reporter gene. For the luciferase assays, reporter plasmids and miR oligos were co-reverse transfected using Lipofectamine 2000. Briefly, 200 ng of plasmid DNA, 60 pmoles of pre-miR oligos and 0.25 ml lipofectamine were complexed individually (25 ml total each) and added in various combinations to 150 ml of 4.5 Â 10 4 cells in 96-well plates. Samples were measured after 48 h using Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) and read on a Fluroskan Ascent FL Microplate Fluorometer (Thermo Electron, Milford, MA, USA) following the manufacturers' procedures. Values are presented as the ratio of renilla to firefly luciferase activity (n ¼ 4 per treatment).
Western blot analysis
Cells were lysed in RIPA (radioimmunoprecipitation assay) buffer (Thermo Scientific, Rockford, IL, USA) and 25-50 mg protein per lane were separated on sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes. Immunoblotting was performed using 1:1000 diluted anti-CASP3 or anti-CASP7 polyclonal rabbit antibodies (Cell Signaling Technology, Danvers, MA, USA; Nos. 9662 and 9492), or an anti-PTEN antibody (No. 9188; Cell Signaling). b-Actin immunoblotting was performed using an anti-mouse b-actin antibody (Calbiochem, San Diego, CA, usa; No. CP01). Protein levels were quantified using ImageJ software (http://rsbweb.nih.gov/ij/) and normalized to b-actin.
CASP3/7 activity assay for apoptosis detection
Cells were plated in 96-well plates (2.5 Â 10 4 cells/well) for 48 h before being treated with 1 mM staurosporine (Sigma, St Louis, MO, USA). CASP3/7 activity was measured after 24 h of staurosporine treatment using the Apo-ONE Homogeneous Caspase 3/7 Assay (Promega).
ECM protein-binding assays
Adhesion assays were performed on pre-coated 96-well Millicoat Cell Adhesion strips (Millipore, Bellerica, MA, USA). Cells were cultured serumfree for 24 h before 1 Â 10 5 cells were plated per well and incubated for 2 h at 37 1C. Bound cells were stained with 0.2% crystal violet in 10% ethanol for 10 min and gently washed with phosphate-buffered saline. In all, 100 ml of Solubilization Buffer (a 1:1 mixture of 0.1M NaH 2 PO 4 , pH 4.5 and 50% ethanol) was added to each well and incubated at room temperature until the cell-bound stain was completely solubilized. The optical density was determined at 570 nm.
Anchorage-independent soft agar growth assay Soft agar assays were performed using the Cytoselect 96-well cell transformation assay kit (Cell Biolabs, San Diego, CA, usa) with a few modifications. Briefly, 50 ml per well of base agar matrix was added to a 96-well plate. After solidification, 2500 or 5000 cells were plated in an agar matrix layer on top of the base. Wells were topped with 50 ml of complete media and incubated for 7 days at 37 1C with 5% CO 2 . Next, 125 ml of matrix solubilization solution was added and 100 ml of this mixture was transferred to a new 96-well plate. To measure metabolically active cells, 10 ml MTS reagent (Promega) was added to each well, incubated for 1-4 h and then measured at 490 nm.
Statistical analysis and bioinformatics
All statistical tests were two-sided, and an association was considered statistically significant with P-valueo0.05. Kaplan-Meier survival method, Cox proportional hazards regression analysis and the log-rank test were used for disease recurrence analyses. Array expression data from cell linebased experiments were analyzed with customized R scripts (http://www. r-project.org) after data normalization within R using robust multi-array average for normalized intensities and MAS5 detection calls to filter out bad probes. Lists of differentially expressed genes were generated with the SAM (significance analysis of microarrays) procedure and defined using P-values from two-sided t-tests, fold changes and/or false discovery rate cutoffs. Publically available miR and mRNA expression data 22 was downloaded as normalized log2 data from the cBio Cancer Genomics Portal (http://cbio.mskcc.org/cancergenomics/prostate/data/). P-values and fold changes were calculated between primary, metastatic and normal adjacent benign prostate tissues using the analysis of variance function within Partek Genomics Suite software (Partek, St Louis, MI, usa). Analysis of CASP7 expression across multiple prostate cancer data sets was carried out within Oncomine (Ann Arbor, MI, USA) and was restricted to data set class comparisons where CASP7 expression was significantly altered between classes. Pathway enrichment was calculated using DAVID (http://david.abcc.ncifcrf.gov/) and expressed as Fisher's exact P-value. The TargetScan database (http://www.targetscan.org) was used to define miR seed sites within mRNA 3 0 -UTRs.
ABBREVIATIONS miR, microRNA; UTR, untranslated region.
